Higher Doses of Semaglutide Show Promise in Weight Loss and Blood Sugar Control

A recent study published in The Lancet has revealed that higher doses of oral Semaglutide, a medication designed for weight loss, have shown promising results in lowering blood sugar levels and facilitating weight loss. Notably, the study included Indian participants, adding to its significance.

Dr. KP Singh, the Director of Endocrinology at Fortis Hospital, Mohali, and the Principal Investigator of the Semaglutide trial in India, suggests that the 25 mg and 50 mg doses exhibited superior control over blood sugar levels and weight reduction when compared to the currently approved highest dose of 14 mg. This finding implies that these higher doses could assist in tailoring individual treatment goals, particularly for addressing body weight and reducing cardiovascular risks. Moreover, Semaglutide is also being investigated for its potential use in treating other conditions, such as Non-Alcoholic Steatohepatitis (NASH). 

Dr. Sandeep S Chhatwal, an Internal Medicine Specialist at Omni Clinics in Chandigarh, explains that Semaglutide is presently administered to obese patients with diabetes in doses of 3 mg, 7 mg, and 14 mg. This medication aids in weight reduction, which helps bridge the demand-supply gap in diabetes management. He raises concern that while most patients tolerate the drug well with minimal issues, higher doses may lead to more frequent gastrointestinal side effects.

Furthermore, the widespread usage of this therapy may face a significant obstacle due to the high cost of the drug. So many setbacks remain that need to be addressed before bringing this therapy to the common people.